JPRN-jRCT2080221274未知2 期
A Multicenter Randomized Double-Blind Placebo-Controlled Parallel-Group Comparison Study in Opioid-Induced Constipation
ONO PHARMACEUTICAL CO.,LTD.0 个研究点目标入组 200 人开始时间: 2010年10月19日最近更新:
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Age 20 years or older.
- •2.Patient with constipation on a stable opioid regimen.
排除标准
- •1.Patients with known or suspected gastrointestinal obstruction.
- •2.Patients with constipation mainly caused by anybowel dysfunction other than opioid-induced one.
研究者
相似试验
进行中（未招募）
1 期
Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus NephritisEUCTR2021-002862-42-BGAstraZeneca AB360
进行中（未招募）
1 期
Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus NephritisActive Proliferative Lupus NephritisMedDRA version: 21.1Level: PTClassification code 10025140Term: Lupus nephritisSystem Organ Class: 10038359 - Renal and urinary disordersEUCTR2021-002862-42-PLAstraZeneca AB360
招募中
1 期
Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus NephritisActive Proliferative Lupus NephritisCTIS2023-506359-68-00Astrazeneca AB336
尚未招募
3 期
A Multicenter Randomized Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Anifrolumab in Adult Patients with Active Proliferative Lupus Nephritisinflammation kidney due to auto-immune disease1000381610038430NL-OMON51523Astra Zeneca8
进行中（未招募）
1 期
Phase 3 Study of Anifrolumab in Adult Patients with Active Proliferative Lupus NephritisEUCTR2021-002862-42-NLAstraZeneca360